The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Characterizing the tumor and immune landscape of melanoma patients treated with combined checkpoint blockade and MAPK targeted therapy.
 
Liron Zisman
No Relationships to Disclose
 
Donald P. Lawrence
No Relationships to Disclose
 
David F. McDermott
Consulting or Advisory Role - alkermes; Array BioPharma; Bristol-Myers Squibb; Calithera Biosciences; Eisai; EMD Serono; exelixis; Genentech/Roche; Iovance Biotherapeutics; Jounce Therapeutics; Lilly; Merck; Novartis; Peloton Therapeutics; Pfizer
Research Funding - alkermes (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Prometheus (Inst)
Other Relationship - Beth Israel Deaconess Medical Center
(OPTIONAL) Uncompensated Relationships - AVEO; X4 Pharma
 
Mofei Liu
No Relationships to Disclose
 
Elizabeth Iannotti Buchbinder
Employment - Alexion Pharmaceuticals (I)
Consulting or Advisory Role - Apexigen; Bristol-Myers Squibb; Novartis; Shionogi
Research Funding - Bristol-Myers Squibb; Checkmate Pharmaceuticals; Genentech/Roche; Lilly; Novartis
 
Irena Gushterova
No Relationships to Disclose
 
Anna L. K. Goyne
No Relationships to Disclose
 
Justine Vanessa Cohen
Consulting or Advisory Role - Bristol-Myers Squibb; Genzyme
 
David Michael Miller
Stock and Other Ownership Interests - Checkpoint Therapeutics
Consulting or Advisory Role - Checkpoint Therapeutics; Merck Sharp & Dohme; Pfizer/EMD Serono; Regeneron; Sanofi/Regeneron
Research Funding - Incyte
Travel, Accommodations, Expenses - Merck Sharp & Dohme; Pfizer; Regeneron; Sanofi/Aventis
 
Thomas LaSalle
No Relationships to Disclose
 
Emily Blaum
No Relationships to Disclose
 
Dennie T. Frederick
No Relationships to Disclose
 
Tatyana Sharova
No Relationships to Disclose
 
Genevieve Marie Boland
Honoraria - Novartis; Takeda
Consulting or Advisory Role - Northwest Biotherapeutics
Research Funding - Olink; Palleon Pharmaceuticals; Takeda; Takeda
Other Relationship - Nektar
 
Anita Giobbie-Hurder
No Relationships to Disclose
 
Moshe Sade-Feldman
No Relationships to Disclose
 
Keren Yizhak
No Relationships to Disclose
 
Nir Hacohen
Stock and Other Ownership Interests - BioNTech; BioNTech (I)
Honoraria - Checkmate Pharmaceuticals; Checkmate Pharmaceuticals (I); Merck; Merck (I); Sanofi; Sanofi (I)
Consulting or Advisory Role - Neon Therapeutics; Neon Therapeutics (I)
Patents, Royalties, Other Intellectual Property - BioNTech; BioNTech (I)
 
Ryan J. Sullivan
Consulting or Advisory Role - alkermes; Asana Biosciences; AstraZeneca; Bristol-Myers Squibb; Eisai; Iovance Biotherapeutics; Merck; Novartis; OncoSec; Pfizer; Replimune
Research Funding - Aeglea Biotherapeutics (Inst); Amgen (Inst); Asana Biosciences (Inst); BeiGene (Inst); BioMed Valley Discoveries (Inst); Compugen (Inst); Deciphera (Inst); Lilly (Inst); Merck (Inst); Moderna Therapeutics (Inst); Neon Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst); Rubius Therapeutics (Inst); Sanofi (Inst); Strategia (Inst); Strategia (Inst); Viralytics (Inst)